


## Sibofimloc

<b>Cat. No.:</b>	HY-12820		
<b>CAS No.:</b>	1616113-45-1		
<b>Molecular Formula:</b>	C <sub>35</sub> H <sub>39</sub> NO <sub>11</sub>		
<b>Molecular Weight:</b>	649.68		
<b>Target:</b>	Bacterial; Antibiotic		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 31 mg/mL (47.72 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.5392 mL	7.6961 mL	15.3922 mL
5 mM	0.3078 mL	1.5392 mL	3.0784 mL
10 mM	0.1539 mL	0.7696 mL	1.5392 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

FimH adhesion<sup>[1][2]</sup>

#### In Vitro

FimH is a TLR4 receptor, expressed on E. coli and other Enterobacteriaceae in host with CD. The inhibition of FimH adhesion, and consequently intracellular replication of adherent-invasive E. coli in epithelial cells, may prevent establishment of a sub-mucosal infection leading to mucosal inflammation and epithelial barrier disruption<sup>[1][2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- 
- bioRxiv. 2023 Aug 18.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Ramtohul, Yeeman K, et al. Preparation of mannose derivatives via coupling and click cycloaddition reactions for treating bacterial infections. From PCT Int. Appl. (2014), WO 2014100158 A1 20140626.

[2]. W Reinisch, et al. P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn's disease (CD), Journal of Crohn's and Colitis, Volume 14, Issue Supplement\_1, January 2020: S479-S480.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA